Prof. Dr. Jai Prakash

Position: Principal Investigator
My Personal Goal: "To develop a toolbox of novel technologies to target and re-program the tumor microenvironment, which provides innovative solutions for early diagnosis and effective treatment of cancer"

Location: ZH 254

About Me

I am a pharmaceutical and entrepreneurial scientist with a strong background in developing novel targeted therapeutics against fibrosis and tumor stroma. My research is highly multi-/inter-disciplinary integrating peptide technology, nanomedicine, biology of cancer and fibrosis, as well as bioengineering to address the biggest challenges in the field of the tumor microenvironment.

I obtained my PhD (cum laude) in 2006 from the University of Groningen on the topic “Renal-specific delivery of anti-fibrotic agents using lysozyme to treat renal fibrosis”. Thereafter, I worked as a Vice President – Preclinical Research at BiOrion Technologies with a joint position at the University of Groningen. During this period, I developed several products, which have been translated by BiOrion. Besides that, I co-supervised PhD students on the topics related to the cell-specific targeting to liver fibrosis. In parallel, I initiated a new research line on "tumor stroma targeting using peptide-based technology". To gain new knowledge and experience in the tumor stroma field, I joined the group of Prof. Arne Östman at Karolinska Institutet in Stockholm by receiving two prestigious grants Swedish Cancer Foundation grant and Marie Curie Career Integration Grant. Shortly, I was promoted to Assistant Professor in the Department of Oncology-Pathology of Karolinska Institutet. I also received Young Researcher Swedish Research Council Project award to develop anti-microRNA targeting approaches against cancer. In late 2012, I was appointed as Tenure-track Assistant Professor in the Department of Biomaterials, Science and Technology, a part of the MIRA Institute (now called TechMed Centre), University of Twente. Since then, I have been focusing on the development of novel technologies aiming to modulate and emulate the tumor microenvironment.

With my invention of a novel peptide, in 2016, I founded a spin-off company ScarTec Therapeutics BV. ScarTec aims to develop novel therapeutic technologies for inhibiting scar formation and pancreatic cancer. ScarTec received NWO/TTW Take-off phase-1 and phase-2 funding earlier.

Recently, ScarTec has successfully obtained European Union's Horizon 2020 SME instrument phase-1 grant (FIBROHALT; 837418).

Image result for logo h2020


Tubantia Newspaper,   “UT sets new steps in the treatment of pancreatic cancer”, 
10 Nov 2017.

 U-Today, Science and Technology magazine  “Novel treatment to kill cancer by targeting stroma” 
Oct, 2017.

“KNCV Golden Master award 2017” to Marcel Heinrich
(PhD student under my supervision), for his master project in my group on "Lipids against Cancer".


see Publications